CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...